PPJ: Journaling and Addiction Recovery: Piloting "Positive Peer Journaling"

Sponsor
University of Minnesota (Other)
Overall Status
Completed
CT.gov ID
NCT04458181
Collaborator
(none)
81
1
2
15.8
5.1

Study Details

Study Description

Brief Summary

The main objective of this study is to pilot test the Positive Peer Journaling (PPJ) intervention and its feasibility and acceptability. A second objective is to compare individuals assigned to PPJ to individuals in a treatment as usual control group.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Positive Peer Journaling (PPJ)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
81 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Journaling and Addiction Recovery: Piloting "Positive Peer Journaling"
Actual Study Start Date :
Jul 7, 2020
Actual Primary Completion Date :
Nov 1, 2021
Actual Study Completion Date :
Nov 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment Group

Participants in this group will complete the intervention, Positive Peer Journaling (PPJ), while also continuing to attend intensive outpatient treatment for addiction.

Behavioral: Positive Peer Journaling (PPJ)
PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve subjective wellbeing in recovery and reduce relapse. PPJ uses journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing "good" and "bad" things that happened and things for which one is grateful. Good wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as "recovery," "work/school," "spirituality," "home and household," and "health."

No Intervention: Control Group

There will be no intervention for those randomized to the control group. However, they will complete assessment instruments throughout the study period while also continuing to attend intensive outpatient treatment for addiction.

Outcome Measures

Primary Outcome Measures

  1. Satisfaction with Life [9 weeks]

    Score on the "Satisfaction with Life" scale. This scale has 5 items assessed on a 7 point Likert-type response format. Scores range from 5 to 35 with higher scores representing higher satisfaction with life.

  2. Happiness with recovery [9 weeks]

    Score on a single item, "In general, I am happy with my recovery." This item uses an 11 point scale ranging from 0 to 11. Higher scores represent higher happiness with recovery.

  3. Commitment to sobriety [9 weeks]

    Score on a single item, "I will do whatever it takes to recover from my addiction." This item uses an 11 point scale ranging from 0-11. Higher scores represent greater commitment to sobriety.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • meet DSM-V criteria for past-year Substance Use Disorder as primary or secondary diagnosis,

  • English literacy sufficient to make short written lists needed to complete PPJ and homework assessments,

  • minimum 2 weeks sustained abstinence,

  • completed first 2 weeks of treatment at Nuway (approximately 2 weeks), an intensive outpatient substance use disorder treatment program and the recruitment site,

  • agree to be audio recorded or transcription recorded in group meetings and in individual meetings with research staff,

  • currently are clients in the Nuway outpatient program,

  • participants must be English speaking and literacy must be strong enough to write short lists and to understand the questions asked in the questionnaires,

  • participants must have an electronic device that connects to the internet and internet connection for online delivery of intervention during COVID-19.

Exclusion Criteria:
  • presence of a psychotic disorder, psychiatric condition (e.g., suicidal ideation), or cognitive impairment (e.g., severe dementia, traumatic brain injury) limiting ability to give consent and/or participate in the study;

  • severe psychiatric illness (current schizophrenia, major depression with suicidal ideation);

  • personality disorders that would interfere with satisfactory participation in or completion of the study protocol,

  • inability to give informed, voluntary consent to participate,

  • lack of sufficient English literacy to participate, defined as inability to make a list of 5 things they did yesterday and inability to understand questionnaire items,

  • any impairment, activity, or situation that in the judgement of the research staff would prevent satisfactory participation in or completion of the study protocol.

Contacts and Locations

Locations

Site City State Country Postal Code
1 NUWAY Minneapolis Minnesota United States 55413

Sponsors and Collaborators

  • University of Minnesota

Investigators

  • Principal Investigator: Amy Krentzman, MSW, PhD, University of Minenesota

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Minnesota
ClinicalTrials.gov Identifier:
NCT04458181
Other Study ID Numbers:
  • STUDY00004619-2
First Posted:
Jul 7, 2020
Last Update Posted:
Dec 15, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 15, 2021